Daniel C. Adelman is a notable inventor based in Redwood City, CA, who has made significant contributions to the field of cancer treatment. With a total of 6 patents to his name, Adelman has focused on developing innovative compounds and methods aimed at combating cancer.

Latest Patents

Among his latest patents are SNS-595 and methods of using the same. This invention relates to SNS-595 and methods of treating cancer using the compound. Additionally, he has developed compounds and compositions for the treatment, prevention, or management of cancer. These compositions include SNS-595 and N-desmethyl-SNS-595, along with pharmaceutical formulations that utilize these compounds for effective treatment.

Career Highlights

Throughout his career, Daniel C. Adelman has worked with prominent companies in the pharmaceutical industry, including Sunesis Pharmaceuticals, Inc. and Sumitomo Dainippon Pharma Co., Ltd. His work in these organizations has contributed to advancements in cancer therapies and has positioned him as a key figure in the field.

Collaborations

Adelman has collaborated with several professionals in his field, including Jeffrey A. Silverman and Marc Evanchik. These partnerships have fostered innovation and have played a crucial role in the development of his patented technologies.

Conclusion

Daniel C. Adelman's work exemplifies the spirit of innovation in the fight against cancer. His contributions through patents and collaborations highlight the importance of research and development in improving treatment options for patients.

This text is generated by artificial intelligence and may not be accurate.